Skip to content

A STEP for Patients Prior to Undergoing TAVR: A Pilot Study

A Supervised TAVR Exercise Program (STEP) for Patients Prior to Undergoing Transcatheter Aortic Valve Replacement (TAVR): A Pilot Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02766075
Acronym
STEP
Enrollment
4
Registered
2016-05-09
Start date
2016-05-31
Completion date
2018-02-28
Last updated
2018-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis, Frail Elderly

Keywords

Transcatheter Aortic Valve Disease, Supervised TAVR Exercise Program

Brief summary

The aim of this pilot study is to establish whether a Supervised TAVR Exercise Program (STEP) can safely improve the frailty status in patients with symptomatic severe aortic valve stenosis prior to undergoing transcatheter aortic valve replacement (TAVR).

Detailed description

TAVR is an approved alternative therapy for patients with severe aortic valve stenosis who are deemed inoperable or high-risk for surgical aortic valve replacement (SAVR). Despite a very high procedural success rate (\>95%), mortality rates after TAVR at 1- and 2-year follow-up remain ≥25% and ≥34%, respectively. It is becoming increasingly evident that frailty, as a clinical syndrome, has a large impact on this long term mortality. In a study by Green, et al. frailty status was independently associated with increased 1-year mortality (OR=3.5) after TAVR. The investigators' own retrospective analysis showed that impaired mobility and malnutrition were significantly associated with a longer hospital length of stay (5 days vs. 3 days), and increased total cost (on average, an additional $10,000 per patient). Given the phenotype of frailty is characterized by reductions in muscle mass, strength, endurance and activity level, a STEP is ideally suited to counteract these impairments. This pilot study aims to establish whether a STEP can safely improve the frailty score in patients with symptomatic severe aortic valve stenosis prior to undergoing TAVR. This single-center pilot study will be conducted in partnership between Heart Care Midwest (HCMW), OSF St. Francis Medical Center (OSF SFMC), and University of Illinois College of Medicine at Peoria (UICOMP). UICOMP Center of Outcomes Research will provide analytical support. The study will be funded by an operational research grant from OSF SFMC.

Interventions

BEHAVIORALSupervised TAVR Exercise Program

Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait & Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.

Sponsors

HeartCare Midwest
CollaboratorUNKNOWN
University of Illinois College of Medicine at Peoria
CollaboratorOTHER
OSF Healthcare System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult patients scheduled to undergo first-time elective TAVR

Exclusion criteria

* Vulnerable populations including prisoners, pregnant females and patients less than 18 years age. * Patients with history of unstable angina, myocardial infarction, or decompensated heart failure in the week prior to screening * Patients with physical limitations (i.e. debilitating stroke, amputation, unable to complete initial screening frailty profile) * Patients with advanced dementia or cognitive deficits (i.e. unable to follow instructions of initial screening frailty profile) * Exercise-induced arrhythmias

Design outcomes

Primary

MeasureTime frame
Change in Frailty Score from Baseline to post-STEPBaseline, 6-weeks

Secondary

MeasureTime frame
Change in Frailty Score from Baseline to 30-days post-TAVRBaseline, 30-days post-TAVR
Change in Gait Speed (5-Meter Walk Test) from Baseline to post-STEPBaseline, 6-weeks
Change in Gait Speed (5-Meter Walk Test) from Baseline to 30-days post-TAVRBaseline, 30-days post-TAVR
Change in Grip Strength (Dynamometer) from Baseline to post-STEPBaseline, 6-weeks
Adverse Events6-weeks
Change in Independent Activity (Katz Activities of Daily Living Survey) from Baseline to post-STEPBaseline, 6-weeks
Change in Independent Activity (Katz Activities of Daily Living Survey) from Baseline to to 30-days post-TAVRBaseline, 30-days post-TAVR
Change in Malnutrition (Serum Albumin Level) from Baseline to 30-days post-TAVRBaseline, 30-days post-TAVR
Change in Grip Strength (Dynamometer) from Baseline to 30-days post-TAVRBaseline, 30-days post-TAVR

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026